{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adverse+Event+Monitoring&page=2", "query": { "intervention": "Adverse Event Monitoring", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Adverse+Event+Monitoring&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-17T22:02:51.910Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02706561", "title": "Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostate Cancer", "Erectile Dysfunction" ], "interventions": [ { "name": "questionnaires", "type": "BEHAVIORAL" }, { "name": "three in-person sessions", "type": "BEHAVIORAL" }, { "name": "monthly phone calls", "type": "BEHAVIORAL" }, { "name": "Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED)", "type": "BEHAVIORAL" }, { "name": "Enhanced Monitoring and Education (EME)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "MALE", "summary": "21 Years and older · Male only" }, "enrollment_count": 224, "start_date": "2015-12-08", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-09-17T22:02:51.910Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02706561" }, { "nct_id": "NCT01191242", "title": "Methadone Monitoring for Insights Into Adverse Events", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pain", "Opiate Addiction" ], "interventions": [], "intervention_types": [], "sponsor": "Intermountain Health Care, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2010-08", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2017-03-29", "last_synced_at": "2026-09-17T22:02:51.910Z", "location_count": 2, "location_summary": "Murray, Utah • Taylorsville, Utah", "locations": [ { "city": "Murray", "state": "Utah" }, { "city": "Taylorsville", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01191242" }, { "nct_id": "NCT06476275", "title": "Single Dose Texas 2017 (H3N2) Challenge Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza Viral Infections" ], "interventions": [ { "name": "Influenza A/Texas/71/2017 (H3N2)", "type": "BIOLOGICAL" }, { "name": "Sham placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "46 Years", "sex": "ALL", "summary": "18 Years to 46 Years" }, "enrollment_count": 33, "start_date": "2024-09-11", "completion_date": "2025-02-10", "has_results": false, "last_update_posted_date": "2025-02-26", "last_synced_at": "2026-09-17T22:02:51.910Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06476275" }, { "nct_id": "NCT01737554", "title": "Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer", "Hematologic Disorders" ], "interventions": [ { "name": "Catheter Resistance Monitoring", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "24 Years", "sex": "ALL", "summary": "5 Years to 24 Years" }, "enrollment_count": 10, "start_date": "2012-12", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2016-12-21", "last_synced_at": "2026-09-17T22:02:51.910Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01737554" }, { "nct_id": "NCT03023449", "title": "Diffuse Optical Monitoring With Inhaled Nitric Oxide", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stroke" ], "interventions": [ { "name": "Nitric Oxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Steven Messe", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 40, "start_date": "2017-04-04", "completion_date": "2026-07", "has_results": false, "last_update_posted_date": "2025-08-24", "last_synced_at": "2026-09-17T22:02:51.910Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03023449" }, { "nct_id": "NCT03018288", "title": "Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "HSPPC-96", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2017-09-21", "completion_date": "2022-12-20", "has_results": true, "last_update_posted_date": "2025-08-08", "last_synced_at": "2026-09-17T22:02:51.910Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03018288" }, { "nct_id": "NCT07733674", "title": "Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma Multiforme (GBM)", "Pancreatic Ductal Adenocarcinoma (PDAC)" ], "interventions": [ { "name": "203Pb-RMX-VHPIB injection", "type": "DRUG" }, { "name": "SPECT/CT Imaging", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Radiomedix, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-08-15", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-09-17T22:02:51.910Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07733674" }, { "nct_id": "NCT04341441", "title": "Will Hydroxychloroquine Impede or Prevent COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19", "Coronavirus", "Coronavirus Infections", "SARS-CoV 2" ], "interventions": [ { "name": "Hydroxychloroquine - Daily Dosing", "type": "DRUG" }, { "name": "Hydroxychloroquine - Weekly Dosing", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "OTHER" }, { "name": "Monitoring Visit - Baseline", "type": "DIAGNOSTIC_TEST" }, { "name": "Monitoring Visit - Week 4", "type": "DIAGNOSTIC_TEST" }, { "name": "Monitoring Visit - Week 8", "type": "DIAGNOSTIC_TEST" }, { "name": "Weekly Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER", "DIAGNOSTIC_TEST" ], "sponsor": "Henry Ford Health System", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 624, "start_date": "2020-04-07", "completion_date": "2020-12-15", "has_results": true, "last_update_posted_date": "2022-06-21", "last_synced_at": "2026-09-17T22:02:51.910Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04341441" }, { "nct_id": "NCT05038254", "title": "Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Metastatic Colon Carcinoma", "Metastatic Esophageal Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Liver Carcinoma", "Metastatic Malignant Digestive System Neoplasm", "Metastatic Malignant Small Intestinal Neoplasm", "Metastatic Malignant Thoracic Neoplasm", "Metastatic Pancreatic Carcinoma", "Metastatic Rectal Carcinoma", "Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IV Gastric Cancer AJCC v8", "Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Stage IVB Rectal Cancer AJCC v8", "Stage IVC Colon Cancer AJCC v8", "Stage IVC Rectal Cancer AJCC v8" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Patient Monitoring", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 750, "start_date": "2021-05-12", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-09-17T22:02:51.910Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05038254" }, { "nct_id": "NCT07663422", "title": "Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Immune-mediated Hepatitis", "Immune-related Adverse Event" ], "interventions": [ { "name": "Mycophenolate Mofetil plus prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2026-07-23", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-09-17T22:02:51.910Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07663422" } ] }